Published on 21 Dec 2023 on Simply Wall St. via Yahoo Finance
Key Insights
Given the large stake in the stock by institutions, Inozyme Pharma's stock price might be vulnerable to their trading decisions53% of the business is held by the top 8 shareholdersOwnership research along with analyst forecasts data help provide a good understanding of opportunities in a stock
Every investor in Inozyme Pharma, Inc. (NASDAQ:INZY) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 45% to be precise, is institutions. Put another way, the group faces the maximum upside potential (or downside risk).